Biologicals as theranostic vehicles in paediatric oncology

Veerle J.A. Niessen, Sylvia T.M. Wenker, Marnix G.E.H. Lam, Max M. van Noesel, Alex J. Poot

Research output: Contribution to journalArticlepeer-review


Biologicals, such as antibodies or antibody-fragments e.g. nanobodies, have changed the landscape of cancer therapy and can be used in combination with traditional cancer treatments. They have been demonstrated to be excellent vehicles for molecular imaging. Several biologicals for nuclear imaging of adult cancer may be used in combination with (nuclear) therapy. Though it's great potential, molecular imaging using biologicals is rarely applied in paediatric oncology. This paper describes the current status of biologicals as radiopharmaceuticals for childhood cancer. Furthermore, the importance and potential for developing additional biological theranostics as opportunity to image and treat childhood cancer is discussed.

Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalNuclear Medicine and Biology
Publication statusPublished - 1 Nov 2022


  • Biologicals
  • Nuclear imaging
  • Paediatric oncology
  • Radionuclide therapy
  • Theranostics
  • Medical Oncology
  • Humans
  • Molecular Imaging
  • Radiopharmaceuticals
  • Child
  • Neoplasms/diagnostic imaging
  • Precision Medicine


Dive into the research topics of 'Biologicals as theranostic vehicles in paediatric oncology'. Together they form a unique fingerprint.

Cite this